On January 30th, County Secretary Aifang Hao, Supervisors from Management Committee of Luotian Economic Development Zone and Luotian Fire Brigade, came to Xinpusheng Pharma for safety inspection. 

FDA approves a new weight loss drug, Zepbound from Eli Lilly BY ALEXANDER TIN UPDATED ON: NOVEMBER 8, 2023 / 8:33 PM EST / CBS NEWS The Food and Drug Administration approved a request by Eli Lilly on Wednesday to begin marketing its tirzepatide medication, which is branded as Mounjaro for diabetes, under a new brand for weight loss as well. While Mounjaro had already been used by some patients "off-label" for weight loss, the new FDA approval will allow the drugmaker to begin officially selling and marketing tirzepatide — branded as Zepbound — for weight loss too. Zepbound will be available for patients in the U.S. by the end of the year, the drugmaker said. The company said Wednesday in a news release that the medication, administered with an injection pen, will be sold at a cheaper list price than its semaglutide competitors from Novo Nordisk, which are branded as Wegovy for weight loss and Ozempic for diabetes.  "New treatment options bring hope to the many people with obesity who struggle with this disease and are seeking better options for weight management," Joe Nadglowski, CEO of the Obesity Action Coalition, said in Eli Lilly's release. The group receives funding from Eli Lilly and other pharmaceutical and health care companies. READ MORE         Bear steals $45 Taco Bell order from Florida family's porchafter Uber Eats delivery The FDA's approval of Zepbound was partially based on a trial of adults without diabetes, which found that participants — who averaged 231 pounds at the start of the trial — who were given the highest approved dose lost around 18% of their body weight compared to placebo. The FDA approved Eli Lilly's drug Zepbound for weight loss.ELI LILLY "In light of increasing rates of both obesity and overweight in the United States, today's approval addresses an unmet medical need," the FDA's Dr. John Sharretts, director of the agency's Division of Diabetes, Lipid Disorders, and Obesity, said in a news release. While there have not been results from large clinical trials comparing Novo Nordisk's and Eli Lilly's medications head-to-head, there is some research to suggest Zepboud could outperform Ozempic.  A meta-analysis presented at the annual meeting of the European Association for the Study of Diabetes in October concluded tirzepatide was "more effective for weight loss than semaglutide, with a larger weight-loss effect at higher doses," but acknowledged limitations in trying to make a direct comparisons of the two. In a report earlier this year comparing semaglutide and tirzepatide for diabetics, the Institute for Clinical and Economic Review concluded that tirzepatide showed "greater reduction" in weight and other key markers, but "had a greater incidence of gastrointestinal side effects, severe adverse events, and discontinuation compared with semaglutide." Zepbound carries the risk of an array of potential side effects, the FDA says, including nausea, diarrhea, vomiting, constipation, and hair loss.  Like with other weight loss drugs in this class, some of Zepbound's side effects could be serious.   People with a history of severe gastroparesis, or stomach paralysis, should not use the drug, the FDA says.  Eli Lilly and Novo Nordisk have both faced claims that their drugs can cause stomach paralysis. The FDA recently moved to acknowledge reports of ileus, or a blockage in the intestines, on Ozempic's label. The agency also notes that other people could be at higher risk of more severe issues from Zepbound, including patients with a history of medullary thyroid cancer, pancreas inflammation, or severe gastrointestinal disease. It also should not be combined with other so-called GLP-1 receptor agonist drugs, which include its sibling Mounjaro, as well as Wegovy and Ozempic. "The safety and effectiveness of coadministration of Zepbound with other medications for weight management have not been established," the agency says. In:  Eli Lilly   Ozempic   Weight Loss Alexander Tin CBS News reporter covering public health and the pandemic.   First published on November 8, 2023 / 1:25 PM EST © 2023 CBS Interactive Inc. All Rights Reserved.   SOURCE→

  Daidzein from Dietary Supplement to a Drug Candidate: An Evaluation of Potential Mohammed Ubaid ,  Salauddin ,  Md Andalib Shadani ,  S. M. Kawish ,  Mohammed Albratty ,  Hafiz A. Makeen ,  Hassan A. Alhazmi ,  Asim Najmi ,  Khalid Zoghebi ,  Maryam A. Halawi ,  Abuzer Ali ,  Md Shamsher Alam* ,  Zeenat Iqbal* , and  Mohd. Aamir Mirza*     Cite this: ACS Omega 2023, 8, 36, 32271–32293 Publication Date:August 27, 2023   https://doi.org/10.1021/acsomega.3c03741 Copyright © 2022 The Authors. Published by American Chemical Society. This publication is licensed under  CC-BY-NC-ND 4.0. Article Views 440 Altmetric - Citations - LEARN ABOUT THESE METRICS Share   Add to   ExportRIS PDF (3 MB)   SUBJECTS: Anatomy, Cancer, Cells, Flavonoids, Peptides and proteins     ACS Omega Abstract Daidzein (DDZ) is a well-known nutraceutical supplement belonging to the class of isoflavones. It is isolated from various sources such as alfalfa, soybean, and red clover. It demonstrates a broad array of pharmacological/beneficial properties such as cardiovascular exercise, cholesterol reduction, and anticancer, antifibrotic, and antidiabetic effects, which make it effective in treating a wide range of diseases. Its structure and operation are the same as those of human estrogens, which are important in preventing osteoporosis, cancer, and postmenopausal diseases. It is thus a promising candidate for development as a phytopharmaceutical. Addressing safety, efficacy, and physicochemical properties are the primary prerequisites. DDZ is already ingested every day in varying amounts, so there should not be a significant safety risk; however, each indication requires a different dose to be determined. Some clinical trials are already being conducted globally to confirm its safety, efficacy, and therapeutic potential. Furthermore, as a result of its therapeutic influence on health, in order to establish intellectual property, patents are utilized. In light of the vast potential of eugenol, this review presents a detailed data collection on DDZ to substantiate the claim to develop it in the therapeutic category. This publication is licensed under CC-BY-NC-ND 4.0. cc1. Introduction ARTICLE SECTIONS Jump To In recent times, natural remedies have been considered as an important kind of approach for cures. Historically, medicinal plants have been utilized to both treat and stave off various illnesses. Natural products have been used for the treatment of different ailments since prehistoric times. According to a fossil study, the first or oldest evidence of the usage of plants as medicines dates back about 60 000 years. (1) This offers a fresh perspective on how the knowledge of traditional medicinal plants is operating and how it might be applied to treat emerging and lifestyle disorders. However, there is growing support for incorporating traditional herbal medicine knowledge into the investigation of new therapeutic agents. Various computational methods for bioprospecting in the postgenomic era can be used to investigate the rich medicinal plant history. (2) While many new medications have been created over the past 50 years utilizing high-throughput screening techniques and combinatorial chemistry, natural products and the chemicals produced from them have remained crucial elements in pharmacopoeias. Only a small number of the estimated 250 000–500 000 plant species currently in existence have been studied scientifically for bioactivities. (3) Therefore, there is a lot of potential for new scientific discoveries to come from plants and other natural products, which may be used to learn a lot about unique chemical structures and their innovative modes of action in the context of developing new drugs. (4) The three main factors driving this trend away from synthetic contemporary pharmaceuticals and toward a wider usage of nutraceuticals are (1) cost effectiveness, (2) safety, and (3) accessibility. (5) Phytoestrogens are phenolic plant compounds that are nonsteroidal and naturally occur and, by virtue of their size and molecular makeup, mirror the steroid estrogens produced by vertebrates. They fall into two categories: flavonoids and nonflavonoids. Isoflavones, coumestans, and prenylflavonoids are examples of flavonoids, whereas lignans are examples of nonflavonoids. (6) Isoflavone phytoestrogens include genistein, daidzein (DDZ), glycitein, biochanin A, and formononetin. Humans primarily obtain isoflavones through their diets from soy and soy products, which are primarily composed of DDZ and genistein. They have estrogenic and/or antiestrogenic effects when ingested. Red clover’s methoxylated isoflavone formononetin is successfully transformed into DDZ in the human gastrointestinal tract; it serves as an indirect source of DDZ. Red clover extract based phytoestrogen dietary supplements are becoming more and more well-liked as an alternative therapy for the management of menopausal symptoms. Isoflavones are thought to be chemoprotective and can be used as an alternative therapy for a variety of hormonal illnesses, including menopausal symptoms, cardiovascular diseases, osteoporosis, and numerous cancer types, including breast and prostate cancers. (7) DDZ (a phytoestrogen that belongs to the category of nonsteroidal estrogens), a nutraceutical ingredient so far, belongs to chemical class of isoflavones. It is a multitargeted herbal moiety that is used to address the challenges of a number of ailments, including osteoporosis, cancer, and inflammation, with antihemolytic, antioxidant, and anti-inflammatory effects. It has also protective properties against some illnesses like diseases of the cardiovascular system, diabetes, osteoporosis, and malignancy of the breast; these are connected by which estrogen control is regulated. Other biological functions not related to the ER (estrogen receptor) include safeguarding the skin and nerves, anti-inflammatory effect, anticancer function, and inhibition of oxidative damage. These positive outcomes are mostly attributable to immunological reaction modulation, oxygen free radical scavenging, proliferation inhibition, and other factors. (8) DDZ has a chemical structure (as shown in Figure 1) similar to that of mammalian estrogens and acts in two directions by either replacing or influencing the ER complex, estrogen receptor, and the hormone estrogen. It can be found in foods produced from soy, such as textured soy protein, soy flour, and soy protein isolates, as well as tofu, tempeh, and miso. Additionally, in supplementary flours made from wheat, rice and maize are fortified with soy flour. (9) 7.1. Anticancer Activity of Daidzein 7.1.1. Breast Cancer of Daidzein 7.1.2. Prostate Cancer of Daidzein 7.1.3. Daidzein Role in Other Types of Cancer 7.2. Daidzein Role in Osteoporosis 7.3. Antidiabetic Activity of Daidzein 7.4. Anti-inflammatory Activity of Daidzein 7.5. Aging and Cognitive Activities of Daidzein 7.6. Daidzein as an Antioxidant 7.7. Role of Daidzein in Cardiovascular Diseases   More info please click the source